Orphan Drug Designation Sends Shares of this Dual-Listed Life Science Therapy Company Soaring

#OrphanDrug designation, or ODD, is valuable on both a humanitarian and a profitability basis. And this company is seeing shares rally following news that it was granted the designation for the treatment of #Pericarditis, the swelling, and irritation of the tissue surrounding the heart. #CardiolTherapeutics (NASDAQ: $CRDL) (TSX: CRDL)